Impairment Loss and Derivative Assets

No definition available.

Name:	lode_ImpairmentLossAndDerivativeAssets
Namespace Prefix:	lode_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Investment in Variable Interest Entity, Equity Interest Issued or Issuable, Number of Shares

+ References

No definition available.

+ Details

Name:	lode_InvestmentInVariableInterestEntityEquityInterestIssuedOrIssuableNumberOfShares
Namespace Prefix:	lode_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_AdditionalPaidInCapital
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

+ Details

Name:	us-gaap_DerivativeAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 35
-Paragraph 32
-URI https://asc.fasb.org/extlink&oid=126903467&loc=d3e32787-111569

+ Details

Name:	us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The loss recognized on termination of a contract.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 275
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126938061&loc=d3e54681-109401

+ Details

Name:	us-gaap_LossOnContractTermination
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_VariableInterestEntityLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=lode_LPBiosciencesLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=lode_LPBiosciencesLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_RestrictedStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

INVESTMENTS - LP Biosciences, LLC (Details) - USD ($)			3 Months Ended
INVESTMENTS - LP Biosciences, LLC (Details) - USD ($)	Feb. 28, 2022	Jul. 23, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Variable Interest Entity [Line Items]
Additional paid-in capital			$ 352,064,106		$ 348,390,556
LP Biosciences LLC
Variable Interest Entity [Line Items]
Impairment loss and derivative assets	$ 5,110,000
Impairment loss	4,173,000
Derivative asset	937,000
Additional paid-in capital	$ 10,812,669
Variable Interest Entity, Not Primary Beneficiary \| LP Biosciences LLC \| Restricted Stock
Variable Interest Entity [Line Items]
Shares issued in connection with investment and financing commitments (in shares)	3,500,000	3,500,000
Loss on contract termination			$ 0	$ 250,000
Variable Interest Entity, Not Primary Beneficiary \| LP Biosciences LLC \| Restricted Stock
Variable Interest Entity [Line Items]
Shares issued in connection with investment and financing commitments (in shares)	3,500,000